XML 22 R9.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The significant accounting policies and estimates used in the preparation of the unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2024, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the United States Securities and Exchange Commission (the “SEC”) on February 28, 2025.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted.
These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed consolidated balance sheet as of December 31, 2024 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements.
Certain reclassifications have been made to prior period amounts to conform to current period presentations. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2025.
Immaterial Correction
As noted in Item 9-B of the Company's Form 10-K for the fiscal year ending December 31, 2024, as filed with the SEC on February 28, 2025, the Company corrected certain misstatements (which the Company determined were not material to the Company’s consolidated financial statements, individually or in the aggregate) in the comparative financial statements including the Condensed Consolidated Statement of Operations, Condensed Consolidated Statement of Comprehensive Loss, Condensed Consolidated Statement of Stockholders' Equity and Condensed Consolidated Statement of Cash Flows for the three and nine months ended September 30, 2024 and applicable footnotes.
The following tables present a summary of the effects of the correction of the Company’s previously issued condensed consolidated financial statements for the three and nine months ended September 30, 2024:
Condensed Consolidated Statements of Operations (unaudited)
Three Months Ended September 30, 2024
Nine Months Ended September 30, 2024
(in thousands)
As Previously Reported
Adjustments
As Corrected
As Previously Reported
Adjustments
As Corrected
General and administrative
$28,515 $3,229 $31,744 $83,104 $9,687 $92,791 
Total operating expenses
93,375 3,229 96,604 281,133 9,687 290,820 
Loss from operations
(10,492)(3,229)(13,721)(33,927)(9,687)(43,614)
Loss before income taxes
(7,208)(3,229)(10,437)(25,322)(9,687)(35,009)
Net loss$(7,408)$(3,229)$(10,637)$(25,461)$(9,687)$(35,148)
Net loss per share
     Basic$(0.14)$(0.06)$(0.20)$(0.49)$(0.18)$(0.67)
     Diluted$(0.14)$(0.06)$(0.20)$(0.49)$(0.18)$(0.67)

Condensed Consolidated Statements of Comprehensive Loss (unaudited)
Three Months Ended September 30, 2024
Nine Months Ended September 30, 2024
(in thousands)
As Previously Reported
Adjustments
As Corrected
As Previously Reported
Adjustments
As Corrected
Net loss$(7,408)$(3,229)$(10,637)$(25,461)$(9,687)$(35,148)
Comprehensive loss(6,623)(3,229)(9,852)(25,677)(9,687)(35,364)

Condensed Consolidated Statement of Stockholders' Equity (unaudited)
Nine Months Ended September 30, 2024
(in thousands)
Additional Paid-in CapitalAccumulated DeficitTotal Stockholders' Equity
As Previously Reported
Balance at December 31, 2023
$946,511 $(678,269)$261,328 
Employee stock-based compensation expense40,090 — 40,090 
Net loss— (25,461)(25,461)
Balance at September 30, 2024984,627 (704,252)273,246 
Adjustments
Employee stock-based compensation expense9,687 — 9,687 
Net loss— (9,687)(9,687)
As Corrected
Balance at December 31, 2023946,511 (678,269)261,328 
Employee stock-based compensation expense49,777 — 49,777 
Net loss— (35,148)(35,148)
Balance at September 30, 2024$994,314 $(713,939)$273,246 
Condensed Consolidated Statement of Cash Flows (unaudited)
Nine Months Ended September 30, 2024
(in thousands)
As Previously Reported
Adjustments
As Corrected
Net loss$(25,461)$(9,687)$(35,148)
Stock-based compensation$40,208 $9,687 $49,895 
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; accrued expenses for clinical studies; inventory valuation; the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.
For the three and nine months ended September 30, 2025, the Company recognized $5.9 million and $1.0 million, respectively, in revenue for tests performed in prior periods, as all performance obligations were satisfied at the time the contract was established.
For the three and nine months ended September 30, 2024, the Company recognized $1.2 million and $18.2 million, respectively, in revenue for tests performed in prior periods, as all performance obligations were satisfied at the time the contract was established.
Concentrations of Credit Risk and Other Risks and Uncertainties
For the three months ended September 30, 2025 and 2024, approximately 32% and 37%, respectively, of total revenue was derived from Medicare. For the nine months ended September 30, 2025 and 2024, approximately 34% and 38%, respectively, of total revenue was derived from Medicare.
As of September 30, 2025 and December 31, 2024, approximately 31% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either September 30, 2025 or December 31, 2024.
Recent Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 340): Improvements to Income Tax Disclosures, which requires annual disclosures in the rate reconciliation table to be presented using both percentages and reporting currency amounts, and this table must include disclosure of specific categories. Additional information will also be required for reconciling items that meet a quantitative threshold. The new guidance also requires enhanced disclosures of income taxes paid, including the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions that exceed a quantitative threshold. The amendments should be applied on a prospective basis, but retrospective application is permitted. This guidance will be effective for the Company’s annual disclosures for the fiscal year ending December 31, 2025, and the Company will update its disclosures accordingly.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. This standard requires entities to disaggregate certain costs and expenses into specific categories and by relevant expense caption in the statement of operations. This guidance will be effective for the Company's annual disclosures for the fiscal year ending December 31, 2027 and for interim period disclosures beginning in the fiscal year ending December 31, 2028. The Company is currently evaluating the potential impact of the new standard on its financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This standard modernizes the accounting guidance for internal-use software costs to better reflect current development practices, including agile and iterative methodologies. This guidance is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. The Company intends to adopt the guidance on a prospective basis upon its effective date and is currently evaluating the impact of the adoption on its financial statements and related disclosures.